Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of Circulating Immune Subsets in Primary Colorectal Cancer.
Lu C, Schardey J, Wirth U, von Ehrlich-Treuenstätt V, Neumann J, Gießen-Jung C, Werner J, Bazhin AV, Kühn F. Lu C, et al. Among authors: giessen jung c. Cancers (Basel). 2022 Dec 12;14(24):6105. doi: 10.3390/cancers14246105. Cancers (Basel). 2022. PMID: 36551592 Free PMC article.
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
Stahler A, Heinemann V, Giessen-Jung C, Crispin A, Schalhorn A, Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Held S, von Einem JC, Holch J, Neumann J, Kirchner T, Jung A, Modest DP. Stahler A, et al. Int J Cancer. 2016 Feb 1;138(3):739-46. doi: 10.1002/ijc.29807. Epub 2015 Sep 18. Int J Cancer. 2016. PMID: 26284333
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Stahler A, Heinemann V, Neumann J, Crispin A, Schalhorn A, Stintzing S, Giessen-Jung C, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Holch JW, Kruger S, Haas M, Michl M, von Einem J, Kirchner T, Jung A, Modest DP. Stahler A, et al. Anticancer Drugs. 2017 Aug;28(7):717-722. doi: 10.1097/CAD.0000000000000510. Anticancer Drugs. 2017. PMID: 28582279 Clinical Trial.
Multidisciplinary treatment of colorectal liver metastases.
Schiergens TS, von Einem J, Thomas MN, Albertsmeier M, Giessen-Jung C, Dörsch M, Heiliger C, Drefs M, Andrassy J, Modest DP, Stintzing S, Guba M, Angele M, Werner J, Rentsch M. Schiergens TS, et al. Minerva Med. 2017 Dec;108(6):527-546. doi: 10.23736/S0026-4806.17.05371-X. Epub 2017 Sep 8. Minerva Med. 2017. PMID: 28889727 Review.
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials.
Stahler A, Stintzing S, Modest DP, Ricard I, Giessen-Jung C, Kapaun C, Ivanova B, Kaiser F, Fischer von Weikersthal L, Moosmann N, Schalhorn A, Stauch M, Kiani A, Held S, Decker T, Moehler M, Neumann J, Kirchner T, Jung A, Heinemann V. Stahler A, et al. Clin Cancer Res. 2020 Dec 15;26(24):6559-6567. doi: 10.1158/1078-0432.CCR-20-2748. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943459
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Stahler A, Heinemann V, Schuster V, Heinrich K, Kurreck A, Gießen-Jung C, Fischer von Weikersthal L, Kaiser F, Decker T, Held S, Graeven U, Schwaner I, Denzlinger C, Schenk M, Neumann J, Kirchner T, Jung A, Kumbrink J, Stintzing S, Modest DP. Stahler A, et al. Eur J Cancer. 2021 Nov;157:71-80. doi: 10.1016/j.ejca.2021.08.017. Epub 2021 Sep 8. Eur J Cancer. 2021. PMID: 34507244 Clinical Trial.
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy.
Alig AHS, Heinemann V, Geissler M, Fischer von Weikersthal L, Decker T, Heinrich K, Held S, Weiss L, Fischer LE, Moosmann N, Stahler A, Jelas I, Kurreck A, von Einem JC, Reinacher-Schick AC, Tannapfel A, Giessen-Jung C, Stintzing S, Modest DP. Alig AHS, et al. Cancers (Basel). 2022 Jan 21;14(3):526. doi: 10.3390/cancers14030526. Cancers (Basel). 2022. PMID: 35158793 Free PMC article.
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
Stahler A, Modest DP, Fischer von Weikersthal L, Kaiser F, Decker T, Held S, Graeven U, Schwaner I, Denzlinger C, Schenk M, Kurreck A, Heinrich K, Gießen-Jung C, Neumann J, Kirchner T, Jung A, Stintzing S, Heinemann V. Stahler A, et al. Among authors: giessen jung c. Eur J Cancer. 2022 Sep;173:194-203. doi: 10.1016/j.ejca.2022.06.019. Epub 2022 Aug 5. Eur J Cancer. 2022. PMID: 35940054
38 results